FDA Brief

Warning letters Drugs

FDA warning letter to

Suprimo Imports

High riskIssued Jun 22, 2023Posted Jun 27, 2023Center for Drug Evaluation and Research | CDER

FDA warns Suprimo Imports that AK Forte and Bob Marley CannaKing are unapproved, misbranded drugs; AK Forte contains hidden prescription ingredients.

What happened

FDA reviewed https://suprimoimports.com/ in January and April 2023 and obtained a sample and labeling of “AK Forte.” Laboratory analysis found that “AK Forte” contains undeclared diclofenac, dexamethasone, and methocarbamol. FDA also cited drug claims for “AK Forte” and “Bob Marley CannaKing” and noted that “Artri Ajo King” was offered for sale, though FDA had not sampled that product from the firm’s inventory.

What FDA found

  1. “AK Forte” and “Bob Marley CannaKing” are sold as drugs without FDA-approved applications.

    Sections 505(a) and 301(d), FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. “AK Forte” labeling does not disclose that it contains diclofenac, dexamethasone, and methocarbamol, so it is misbranded.

    Section 502(a) and 201(n), FD&C Act, 21 U.S.C. 352(a) and 321(n)
  3. “AK Forte” is outside the dietary supplement definition because diclofenac and dexamethasone were approved as drugs before being marketed as supplements or food.

    Section 201(ff)(3)(B)(i), FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i)
  4. “Bob Marley CannaKing” labeling lacks adequate directions for use.

    Section 502(f)(1), FD&C Act, 21 U.S.C. 352(f)(1); 21 CFR 201.5
  5. “Bob Marley CannaKing” is outside the dietary supplement definition because CBD was not marketed as a dietary supplement or food before new drug investigations were authorized.

    Sections 201(ff)(3)(B)(i) and (ii), FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii)
  6. FDA documented that “Artri Ajo King” was offered for sale and said prior FDA analysis found undeclared diclofenac; FDA had not sampled this product from the firm’s inventory.

What FDA wants

Submit a written response within fifteen working days from receipt explaining the steps taken to address the violations and prevent recurrence, with supporting documents, or provide reasoning and information if you believe the products are not in violation.

Who should pay attention

  • retailers and online marketplaces selling imported supplements
  • distributors of “Artri” or similarly named pain products
  • consumers using imported supplements for pain or arthritis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk